Page 1112 - Hematology_ Basic Principles and Practice ( PDFDrive )

980.e2 Part VII Hematologic Malignancies

39. O’Donnell PV, Luznik L, Jones RJ, et al: Nonmyeloablative bone 57. Koreth J, Kim HT, Nikiforow S, et al: Donor chimerism early after
marrow transplantation from partially HLA-mismatched related donors reduced-intensity conditioning hematopoietic stem cell transplantation
using posttransplantation cyclophosphamide. Biol Blood Marrow Trans- predicts relapse and survival. Biol Blood Marrow Transplant 20:1516,
plant 8:377, 2002. 2014.
40. Luznik L, O’Donnell PV, Symons HJ, et al: HLA-haploidentical 58. Reshef R, Hexner EO, Loren AW, et al: Early donor chimerism levels
bone marrow transplantation for hematologic malignancies using predict relapse and survival after allogeneic stem cell transplantation
nonmyeloablative conditioning and high-dose, posttransplantation with reduced-intensity conditioning. Biol Blood Marrow Transplant
cyclophosphamide. Biol Blood Marrow Transplant 14:641, 2008. 20:1758, 2014.
41. Kanakry CG, O’Donnell PV, Furlong T, et al: Multi-institutional study 59. Kroger N, Miyamura K, Bishop MR: Minimal residual disease fol-
of post-transplantation cyclophosphamide as single-agent graft-versus- lowing allogeneic hematopoietic stem cell transplantation. Biol Blood
host disease prophylaxis after allogeneic bone marrow transplantation Marrow Transplant 17:S94, 2011.
using myeloablative busulfan and fludarabine conditioning. J Clin 60. Anthias C, Dignan FL, Morilla R, et al: Pre-transplant MRD predicts
Oncol 32:3497, 2014. outcome following reduced-intensity and myeloablative allogeneic
42. Di Stasi A, Milton DR, Poon LM, et al: Similar transplantation hemopoietic SCT in AML. Bone Marrow Transplant 49:679, 2014.
outcomes for acute myeloid leukemia and myelodysplastic syndrome 61. Chen YB, Li S, Lane AA, et al: Phase I trial of maintenance sorafenib
patients with haploidentical versus 10/10 human leukocyte antigen- after allogeneic hematopoietic stem cell transplantation for FMS-like
matched unrelated and related donors. Biol Blood Marrow Transplant tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
20:1975, 2014. Biol Blood Marrow Transplant 20:2042, 2014.
43. Duval M, Klein JP, He W, et al: Hematopoietic stem-cell transplanta- 62. de Lima M, Giralt S, Thall PF, et al: Maintenance therapy with low-dose
tion for acute leukemia in relapse or primary induction failure. J Clin azacitidine after allogeneic hematopoietic stem cell transplantation for
Oncol 28:3730, 2010. recurrent acute myelogenous leukemia or myelodysplastic syndrome: a
44. Ho VT, Vanneman M, Kim H, et al: Biologic activity of irradiated, dose and schedule finding study. Cancer 116:5420, 2010.
autologous, GM-CSF-secreting leukemia cell vaccines early after allo- 63. Porter DL, Alyea EP, Antin JH, et al: NCI First International Workshop
geneic stem cell transplantation. Proc Natl Acad Sci USA 106:15825, on the Biology, Prevention, and Treatment of Relapse after Allogeneic
2009. Hematopoietic Stem Cell Transplantation: report from the Committee
45. Armand P, Kim HT, Cutler CS, et al: A prognostic score for patients on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell
with acute leukemia or myelodysplastic syndromes undergoing allo- Transplantation. Biol Blood Marrow Transplant 16:1467, 2010.
geneic stem cell transplantation. Biol Blood Marrow Transplant 14:28, 64. Schmid C, Labopin M, Nagler A, et al: Donor lymphocyte infusion
2008. in the treatment of first hematological relapse after allogeneic stem-cell
46. Litzow MR, Tarima S, Perez WS, et al: Allogeneic transplantation for transplantation in adults with acute myeloid leukemia: a retrospective
therapy-related myelodysplastic syndrome and acute myeloid leukemia. risk factors analysis and comparison with other strategies by the EBMT
Blood 115:1850, 2010. Acute Leukemia Working Party. J Clin Oncol 25:4938, 2007.
47. Lindsley RC, Mar BG, Mazzola E, et al: Acute myeloid leukemia 65. Maury S, Lemoine FM, Hicheri Y, et al: Cd4+cd25+ regulatory t cell
ontogeny is defined by distinct somatic mutations. Blood 125:1367, depletion improves the graft-versus-tumor effect of donor lymphocytes
2015. after allogeneic hematopoietic stem cell transplantation. Sci Transl Med
48. Genovese G, Kahler AK, Handsaker RE, et al: Clonal hematopoiesis 2:41ra52, 2010.
and blood-cancer risk inferred from blood DNA sequence. N Engl J 66. Platzbecker U, Bornhäuser M, Germing U, et al: Red blood cell trans-
Med 371:2477, 2014. fusion dependence and outcome after allogeneic peripheral blood stem
49. Jaiswal S, Fontanillas P, Flannick J, et al: Age-related clonal hemato- cell transplantation in patients with de novo myelodysplastic syndrome
poiesis associated with adverse outcomes. N Engl J Med 371:2488, (MDS). Biol Blood Marrow Transplant 14:1217, 2008.
2014. 67. Eapen M, Giralt SA, Horowitz MM, et al: Second transplant for
50. McClune BL, Weisdorf DJ, Pedersen TL, et al: Effect of age on acute and chronic leukemia relapsing after first HLA-identical sibling
outcome of reduced-intensity hematopoietic cell transplantation for transplant. Bone Marrow Transplant 34:721, 2004.
older patients with acute myeloid leukemia in first complete remission 68. Tefferi A, Vardiman JW: Myelodysplastic syndromes. N Engl J Med
or with myelodysplastic syndrome. J Clin Oncol 28:1878, 2010. 361:1872, 2009.
51. Koreth J, Aldridge J, Kim HT, et al: Reduced-intensity condition- 69. Aul C, Germing U, Gattermann N, et al: Increasing incidence
ing hematopoietic stem cell transplantation in patients over 60 years: of myelodysplastic syndromes: real or fictitious? Leuk Res 22:93,
hematologic malignancy outcomes are not impaired in advanced age. 1998.
Biol Blood Marrow Transplant 16:792, 2010. 70. Goldberg SL, Chen E, Corral M, et al: Incidence and clinical complica-
52. Farag SS, Maharry K, Zhang MJ, et al: Comparison of reduced-intensity tions of myelodysplastic syndromes among United States Medicare
hematopoietic cell transplantation with chemotherapy in patients aged beneficiaries. J Clin Oncol 28:2847, 2010.
60-70 years with acute myelogenous leukemia in first remission. Biol 71. Ma X, Does M, Raza A, et al: Myelodysplastic syndromes: incidence
Blood Marrow Transplant 17:1796, 2011. and survival in the United States. Cancer 109:1536, 2007.
53. Lazenby M, Gilkes AF, Marrin C, et al: The prognostic relevance of 72. Garcia-Manero G: Myelodysplastic syndromes: 2011 update on
FLT3 and NPM1 mutations on older patients treated intensively or diagnosis, risk-stratification, and management. Am J Hematol 86:490,
non-intensively: a study of 1312 patients in the UK NCRI AML16 2011.
trial. Leukemia 28:1953, 2014. 73. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Efficacy of azacitidine
54. Ostronoff F, Othus M, Lazenby M, et al: Prognostic significance of compared with that of conventional care regimens in the treatment
npm1 mutations in the absence of flt3-internal tandem duplication in of higher-risk myelodysplastic syndromes: a randomised, open-label,
older patients with acute myeloid leukemia: a SWOG and UK National phase III study. Lancet Oncol 10:223, 2009.
Cancer Research Institute/Medical Research Council report. J Clin 74. Saber W, Cutler CS, Nakamura R, et al: Impact of donor source on
Oncol 33:1157, 2015. hematopoietic cell transplantation outcomes for patients with myelo-
55. Rollig C, Bornhauser M, Kramer M, et al: Allogeneic stem-cell trans- dysplastic syndromes (MDS). Blood 122:1974, 2013.
plantation in patients with NPM1-mutated acute myeloid leukemia: 75. Greenberg P, Cox C, LeBeau MM, et al: International scoring system
results from a prospective donor versus no-donor analysis of patients for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079,
after upfront HLA typing within the SAL-AML 2003 trial. J Clin Oncol 1997.
33:403, 2015. 76. Deeg HJ, Storer B, Slattery JT, et al: Conditioning with targeted busul-
56. Kayser S, Zucknick M, Dohner K, et al: Monosomal karyotype in adult fan and cyclophosphamide for hemopoietic stem cell transplantation
acute myeloid leukemia: prognostic impact and outcome after different from related and unrelated donors in patients with myelodysplastic
treatment strategies. Blood 119:551, 2012. syndrome. Blood 100:1201, 2002.